Background and Aims: Egypt had controlled liver cirrhosis who received HCV vaccine in line to modulate its impact among nephrotic patients. Current clinical trial aim to investigate acute kidney injury (AKI) impact among liver cirrhosis individuals who received HCV treatment. Material and methods: A prospective, multi-center clinical trial, on 50 liver cirrhosis patients who eligible to receive HCV treatment. They equally divided into Group A 25 patient with eGFR >90 ml/min, Group B 25 patients with chronic kidney disease (CKD) stages II-TTT (eGFR <90, >30 mL/min). Fluctuations in serum creatinine, and eGFR evaluated while on-therapy, and by the end of the trail. Results: Both groups A and B revealed significant differences in reading of serum creatinine during and by the end of the study (p < 0.005). the impact of AKI was moredetermined with eGFR >90 ml/min in compare with who had eGFR <90 mi/min and >45 ml/min (p < 0.005). Conclusion: Impact of AKI were reported in their kidney functions especially patients with normal serum creatinine than among liver cirrhosis patients who revealed improvements by the end of the study.
